TY - JOUR
T1 - Safety of using hepatitis B virus core antibody or surface antigen-positive donors in kidney or pancreas tranplantation
AU - Akalin, Enver
AU - Ames, Scott
AU - Sehgal, Vinita
AU - Murphy, Barbara
AU - Bromberg, Jonathan S.
PY - 2005/6
Y1 - 2005/6
N2 - Hepatitis B virus core antibody (HBcAb) or surface antigen (HBsAg)-positive organ donors have the potential to transmit infection to transplant recipients. We investigated the safety of using HBcAb(+) or HBsAg(+) donors in kidney or pancreas transplant recipients with 1 yr lamivudine prophylaxis. While HBsAb(-) recipients of HBcAb(+) donors received prophylaxis, HBsAb(+) recipients did not. HBsAg(+) organs were only used in patients who were both HBcAb and HBsAb(+). Forty-six patients received HBcAb(+) and four received HBsAg(+) organs (47 kidney, two pancreas, and one kidney/pancreas). All but one recipient were HBsAg(-), 25 were HBsAb(+), and 19 HBcAb(+). During a median 36 months of follow-up (range 6-66 months), with 43 of a total 50 patients having at least 1 yr follow-up and were off lamivudine, and none of the patients developed hepatitis B viremia or seroconversion to HBsAg or HBsAb(+). These results suggest that HBcAb(+) or HBsAg(+) organs can be used safely in selected recipients with lamivudine prophylaxis without requiring hepatitis B immunglobulin.
AB - Hepatitis B virus core antibody (HBcAb) or surface antigen (HBsAg)-positive organ donors have the potential to transmit infection to transplant recipients. We investigated the safety of using HBcAb(+) or HBsAg(+) donors in kidney or pancreas transplant recipients with 1 yr lamivudine prophylaxis. While HBsAb(-) recipients of HBcAb(+) donors received prophylaxis, HBsAb(+) recipients did not. HBsAg(+) organs were only used in patients who were both HBcAb and HBsAb(+). Forty-six patients received HBcAb(+) and four received HBsAg(+) organs (47 kidney, two pancreas, and one kidney/pancreas). All but one recipient were HBsAg(-), 25 were HBsAb(+), and 19 HBcAb(+). During a median 36 months of follow-up (range 6-66 months), with 43 of a total 50 patients having at least 1 yr follow-up and were off lamivudine, and none of the patients developed hepatitis B viremia or seroconversion to HBsAg or HBsAb(+). These results suggest that HBcAb(+) or HBsAg(+) organs can be used safely in selected recipients with lamivudine prophylaxis without requiring hepatitis B immunglobulin.
KW - Hepatitis B core antibody
KW - Kidney transplantation
KW - Lamivudine
UR - http://www.scopus.com/inward/record.url?scp=19044386801&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=19044386801&partnerID=8YFLogxK
U2 - 10.1111/j.1399-0012.2005.00350.x
DO - 10.1111/j.1399-0012.2005.00350.x
M3 - Article
C2 - 15877799
AN - SCOPUS:19044386801
SN - 0902-0063
VL - 19
SP - 364
EP - 366
JO - Clinical Transplantation
JF - Clinical Transplantation
IS - 3
ER -